Endocannabinoid System Genes Are Disrupted in Inflamed Bowel Disease Tissue
Six of ten endocannabinoid system genes were dysregulated in inflamed IBD tissue, with some suppressed and others overexpressed, suggesting the system plays an active role in gut inflammation.
Quick Facts
What This Study Found
In IBD patients, FAAH, PPARG, and TRPV1 were significantly downregulated in inflamed mucosa compared to non-inflamed tissue and controls. CB2 and GPR55 receptors were upregulated in inflamed tissue. These patterns were consistent across both Crohn's disease and ulcerative colitis.
Key Numbers
FAAH downregulated in inflamed vs non-inflamed (p=0.012). PPARG downregulated (p=0.001). TRPV1 downregulated (p=0.032). CB2 upregulated (p=0.005). GPR55 upregulated (p=0.001). 6 of 10 ECS genes dysregulated.
How They Did This
Paired biopsies of inflamed and non-inflamed colonic mucosa from 30 IBD patients (17 UC, 13 CD) plus 17 non-IBD controls were analyzed using quantitative PCR for 10 endocannabinoid system genes.
Why This Research Matters
Finding specific patterns of ECS gene dysregulation in inflamed gut tissue provides molecular evidence for why cannabinoid-based therapies might help IBD. The upregulation of CB2 receptors in inflamed tissue suggests the body is actively trying to use the endocannabinoid system to fight inflammation.
The Bigger Picture
This study adds to mounting evidence that the endocannabinoid system is disrupted in IBD. The specific pattern of changes could guide which cannabinoid receptor targets might be most therapeutically relevant for different aspects of gut inflammation.
What This Study Doesn't Tell Us
Small sample size (30 IBD patients, 17 controls). Cross-sectional design cannot determine whether ECS changes cause or result from inflammation. Gene expression does not always correlate with protein levels or functional activity.
Questions This Raises
- ?Could targeting the upregulated CB2 receptors in inflamed gut tissue provide therapeutic benefit?
- ?Do these gene expression changes normalize when IBD is in remission?
Trust & Context
- Key Stat:
- 6 of 10 ECS genes dysregulated in inflamed IBD tissue
- Evidence Grade:
- Original human tissue study with paired biopsies, but limited by small sample size and cross-sectional design.
- Study Age:
- 2026 study.
- Original Title:
- Altered endocannabinoid system gene expression in inflammatory bowel disease mucosa: New perspectives in inflammatory bowel disease management.
- Published In:
- World journal of gastrointestinal endoscopy, 18(2), 113576 (2026)
- Authors:
- Pelisenco, Iulia Andreea, Salvi, Alessandro, De Petro, Giuseppina, Musat, Ioana Andreea, Manuc, Teodora Ecaterina, Tieranu, Cristian George, Becheanu, Gabriel, Milanesi, Elena, Dobre, Maria
- Database ID:
- RTHC-08548
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
What does this mean for cannabis and IBD?
It shows the endocannabinoid system is actively disrupted in IBD, providing a biological rationale for why cannabinoid therapies might help. But this is molecular evidence, not a clinical treatment study.
Why were some ECS genes up and others down?
The body appears to be mounting a compensatory response. CB2 receptor upregulation in inflamed tissue may be an attempt to dampen inflammation, while FAAH downregulation could increase endocannabinoid levels locally.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-08548APA
Pelisenco, Iulia Andreea; Salvi, Alessandro; De Petro, Giuseppina; Musat, Ioana Andreea; Manuc, Teodora Ecaterina; Tieranu, Cristian George; Becheanu, Gabriel; Milanesi, Elena; Dobre, Maria. (2026). Altered endocannabinoid system gene expression in inflammatory bowel disease mucosa: New perspectives in inflammatory bowel disease management.. World journal of gastrointestinal endoscopy, 18(2), 113576. https://doi.org/10.4253/wjge.v18.i2.113576
MLA
Pelisenco, Iulia Andreea, et al. "Altered endocannabinoid system gene expression in inflammatory bowel disease mucosa: New perspectives in inflammatory bowel disease management.." World journal of gastrointestinal endoscopy, 2026. https://doi.org/10.4253/wjge.v18.i2.113576
RethinkTHC
RethinkTHC Research Database. "Altered endocannabinoid system gene expression in inflammato..." RTHC-08548. Retrieved from https://rethinkthc.com/research/pelisenco-2026-altered-endocannabinoid-system-gene
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.